Sai Life Sciences delivered robust financial performance in the June 2026 quarter, with consolidated net profit rising 21.22% to ₹73.29 crore compared to ₹60.46 crore in the corresponding quarter of the previous year. According to reports from Business Standard, this significant profit growth demonstrates the company's operational efficiency and market positioning during the quarter. The company's standalone profit after tax was ₹713.39 million for the quarter ended June 30, 2026, while consolidated profit after tax reached ₹732.85 million. The financial statements encompass results from the company's subsidiaries including Sai Life Sciences Inc, Sai Life GmBH, and Sai Life Pharma Private Limited, collectively referred to as 'the Group'.
The company's sales revenue increased 11.66% to ₹554.29 crore in Q1 FY2026, up from ₹496.42 crore in the same quarter of the previous fiscal year. As reported by Business Standard, this revenue growth indicates strong demand for the company's products and services in the pharmaceutical sector. On a standalone basis, total income reached ₹5,502.72 million for the quarter ended June 30, 2026, while consolidated total income amounted to ₹5,578.28 million. The company's profit before tax (PBT) stood at ₹953.34 million on standalone basis and ₹979.74 million on consolidated basis, reflecting strong operational performance during the quarter.
The company's operating profit margin (OPM) improved to 26.70% in the June 2026 quarter, compared to 24.36% in the corresponding quarter of the previous year. According to the financial data reported by Business Standard, this margin expansion reflects enhanced operational efficiency and cost management initiatives during the quarter. The EBITDA margin expanded by 230 basis points to 26.7%, compared with 24.4% in the same quarter last year, indicating stronger operating leverage during the quarter. On standalone basis, the company reported earnings per equity share (EPS) of ₹3.36 (Basic) and ₹3.33 (Diluted).
Despite strong financial performance, Sai Life Sciences shares fell over 6% to ₹1,327.20 on Friday following the Q1FY27 results announcement. The stock opened in negative 2.72% at ₹1,375 and then tumbled further, with the scrip falling as much as 6.65% to ₹1,322. This compares to a 0.17% fall in the NSE Nifty 50 Index. The stock has risen 72.14% in the last 12 months and 49.16% year-to-date, with total traded volume at 0.43 times its 30-day average. Out of nine analysts tracking the company, all maintain a 'buy' rating according to Bloomberg data, with the average 12-month consensus price target of ₹1,393.44 implying a downside of 1.4%.
